← Back to Search

Anti-metabolites

Chemotherapy Combinations for Breast Cancer

Phase 2

Waitlist Available

Led By Ruth O'Regan, MD

Research Sponsored by Georgia Center for Oncology Research & Education

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Early stage breast cancer (stage 1, 2, 3)

No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new chemotherapy combination to see if it is more effective at shrinking breast tumors and preserving the breast than current treatments.

Who is the study for?

This trial is for adults over 18 with early stage breast cancer (stages 1-3) who haven't had previous treatments or major surgery within the last month. It's not open to those with cancer spread to the brain.Check my eligibility

What is being tested?

The study is testing two chemotherapy regimens: one where docetaxel is given before capecitabine, and another where both drugs are given at the same time, aiming to shrink breast tumors effectively.See study design

What are the potential side effects?

Docetaxel and capecitabine can cause side effects like nausea, fatigue, hair loss, low blood cell counts leading to infection risk, mouth sores, and hand-foot syndrome.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My breast cancer is in an early stage (1, 2, or 3).

Select...

My cancer is only in my breast or chest wall, except for lymph nodes under my arm.

Select...

I am 18 years old or older.

Select...

My breast cancer diagnosis was confirmed through tissue examination.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Georgia Center for Oncology Research & EducationLead Sponsor

1 Previous Clinical Trials

51 Total Patients Enrolled

1 Trials studying Breast Cancer

51 Patients Enrolled for Breast Cancer

SanofiIndustry Sponsor

2,163 Previous Clinical Trials

3,512,380 Total Patients Enrolled

52 Trials studying Breast Cancer

24,229 Patients Enrolled for Breast Cancer

Ruth O'Regan, MDPrincipal InvestigatorEmory University

4 Previous Clinical Trials

117 Total Patients Enrolled

3 Trials studying Breast Cancer

80 Patients Enrolled for Breast Cancer

Media Library

Capecitabine (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00415285 — Phase 2

Breast Cancer Clinical Trial 2023: Capecitabine Highlights & Side Effects. Trial Name: NCT00415285 — Phase 2

Capecitabine (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00415285 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment actively searching for participants at the moment?

"According to clinicaltrials.gov, this study is not actively enrolling patients at present. Originally posted in December 2006 and last modified on February 12th 2007, there are 2287 other trials taking partients presently instead of this one."

Answered by AI

What potential harm may arise from this particular therapy?

"Based on the limited data available, we have rated this treatment's safety at a 2. While Phase 2 trials provide some preliminary evidence of its security, there is yet to be any proof that it may be efficacious."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer

2006. "Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00415285.

All > Paid Studies Georgia > Breast